At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Azacitidine (Vidaza) and Nab-paclitaxel (Abraxane) for Advanced or Metastatic Solid Tumors and Advanced or Metastatic Breast Cancer. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this clinical trial is to test whether treatment of patients with advanced or metastatic solid tumors or breast cancer with Abraxane plus Vidaza is safe and results in good tumor response. All patients enrolling in this study will receive treatment with Abraxane and Vidaza. Safety will be assessed by adverse events, laboratory results and performance status. Tumor response will be measured by RECIST criteria.
Study Details
Timeline
Interventions
50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
100mg/m2 weekly for 3 weeks of each 4-week cycle